Loading
A phase 1/2 trial of BNT329 in advanced solid tumours, run by BioNTech SE, now recruiting.
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 is a phase 1/2 interventional study registered as NCT07186842 by BioNTech SE, with 245 participants planned, started 2025-11-18 and due to reach its primary completion in 2030-05. Interventions recorded: BNT329 and CA19-9-targeting monoclonal antibody.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/